Lumos Pharma (LUMO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LUMO Stock Forecast

Lumos Pharma stock forecast is as follows: an average price target of $16.50 (represents a 281.94% upside from LUMO’s last price of $4.32) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

LUMO Price Target

The average price target for Lumos Pharma (LUMO) is $16.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $7.00. This represents a potential 281.94% upside from LUMO's last price of $4.32.

LUMO Analyst Ratings

Buy

According to 5 Wall Street analysts, Lumos Pharma's rating consensus is 'Buy'. The analyst rating breakdown for LUMO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Lumos Pharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 08, 2022	-	Jefferies	$7.00	$4.46	56.95%	62.04%
May 10, 2022	Yasmeen Rahimi	Piper Sandler	$26.00	$8.05	222.98%	501.85%

Row per page

Go to

The latest Lumos Pharma stock forecast, released on Dec 08, 2022 by Jefferies company, set a price target of $7.00, which represents a 56.95% increase from the stock price at the time of the forecast ($4.46), and a 62.04% increase from LUMO last price ($4.32).

Lumos Pharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$4.32	$4.32	$4.32
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Lumos Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lumos Pharma's last price of $4.32. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	H.C. Wainwright	-	Neutral	Downgrade
Sep 24, 2024	EF Hutton	-	Buy	Initialise
May 15, 2024	Oppenheimer	Outperform	Outperform	Hold
Nov 14, 2022	Jefferies	-	Hold	Downgrade
May 10, 2022	Piper Sandler	Overweight	Overweight	Hold

Row per page

Go to

Lumos Pharma's last stock rating was published by H.C. Wainwright on Oct 24, 2024. The company Downgrade its LUMO rating from "null" to "Neutral".

Lumos Pharma Financial Forecast

Lumos Pharma Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.00K	$527.00K	$691.00K	$512.00K	$497.00K	$403.00K	$111.00K	$40.00K	$74.00K
Avg Forecast	$1.71M	$1.63M	$1.55M	$1.47M	$1.40M	$1.33M	$1.27M	$1.20M	$1.14M	$1.09M	$1.03M	$982.89K	$150.00K	$150.00K	$150.00K	$150.00K	$5.33M	$302.50K	$265.00K	$300.00K	$1.75K	$225.40K	$365.17K	$222.40K	$114.33K	$66.67K	$18.50K	$107.26K	$25.00K	$2.60M
High Forecast	$3.29M	$3.13M	$2.98M	$2.83M	$2.69M	$2.56M	$2.43M	$2.31M	$2.20M	$2.09M	$1.99M	$1.89M	$288.35K	$288.35K	$288.35K	$288.35K	$10.39M	$581.51K	$509.42K	$576.70K	$3.36K	$225.60K	$701.98K	$427.53K	$219.79K	$66.67K	$18.50K	$128.71K	$25.00K	$2.60M
Low Forecast	$131.38K	$124.91K	$118.76K	$112.91K	$107.35K	$102.07K	$97.04K	$92.27K	$87.72K	$83.40K	$79.30K	$75.39K	$11.51K	$11.51K	$11.51K	$11.51K	$265.06K	$23.20K	$20.33K	$23.01K	$134.00	$225.20K	$28.01K	$17.06K	$8.77K	$66.67K	$18.50K	$85.81K	$25.00K	$2.60M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	1	1	1	1	4	4	11	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.03%	1.44%	3.11%	4.48%	7.45%	21.78%	1.03%	1.60%	0.03%

Lumos Pharma's average Quarter revenue forecast for Dec 23 based on 2 analysts is $1.75K, with a low forecast of $134.00, and a high forecast of $3.36K. LUMO's average Quarter revenue forecast represents a -75.00% decrease compared to the company's last Quarter revenue of $7.00K (Sep 23).

Lumos Pharma EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	1	1	1	1	4	4	11	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-8.93M	$-9.64M	$-8.03M	$-9.22M	$-7.25M	$-7.84M	$-7.71M	$-6.86M	$-512.00K
Avg Forecast	$-1.71M	$-1.63M	$-1.55M	$-1.47M	$-1.40M	$-1.33M	$-1.27M	$-1.20M	$-1.14M	$-1.09M	$-1.03M	$-982.89K	$-150.00K	$-150.00K	$-150.00K	$-150.00K	$-5.33M	$-302.50K	$-265.00K	$-300.00K	$-1.75K	$-225.40K	$-365.17K	$-222.40K	$-114.33K	$-66.67K	$-18.50K	$-7.44M	$-25.00K	$-2.60M
High Forecast	$-131.38K	$-124.91K	$-118.76K	$-112.91K	$-107.35K	$-102.07K	$-97.04K	$-92.27K	$-87.72K	$-83.40K	$-79.30K	$-75.39K	$-11.51K	$-11.51K	$-11.51K	$-11.51K	$-265.06K	$-23.20K	$-20.33K	$-23.01K	$-134.00	$-225.20K	$-28.01K	$-17.06K	$-8.77K	$-66.67K	$-18.50K	$-5.95M	$-25.00K	$-2.60M
Low Forecast	$-3.29M	$-3.13M	$-2.98M	$-2.83M	$-2.69M	$-2.56M	$-2.43M	$-2.31M	$-2.20M	$-2.09M	$-1.99M	$-1.89M	$-288.35K	$-288.35K	$-288.35K	$-288.35K	$-10.39M	$-581.51K	$-509.42K	$-576.70K	$-3.36K	$-225.60K	$-701.98K	$-427.53K	$-219.79K	$-66.67K	$-18.50K	$-8.93M	$-25.00K	$-2.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.63%	26.41%	36.09%	80.69%	108.70%	424.00%	1.04%	274.32%	0.20%

undefined analysts predict LUMO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lumos Pharma's previous annual EBITDA (undefined) of $NaN.

Lumos Pharma Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	1	1	1	1	4	4	11	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-8.30M	$-8.93M	$-6.66M	$-7.67M	$-6.95M	$-7.76M	$-7.71M	$-2.42M	$1.76M
Avg Forecast	$-1.62M	$-1.46M	$-1.36M	$-1.43M	$-1.90M	$-1.71M	$-1.59M	$-1.67M	$-2.12M	$-1.92M	$-1.78M	$-2.81M	$-2.47M	$-2.86M	$-2.53M	$-2.49M	$-3.72M	$-6.10M	$-9.77M	$-9.46M	$-9.48M	$-9.56M	$-9.13M	$-9.29M	$-7.76M	$-8.18M	$-8.00M	$-7.46M	$-6.99M	$-5.23M
High Forecast	$323.90K	$292.21K	$271.53K	$286.04K	$379.61K	$342.25K	$318.06K	$335.24K	$425.31K	$383.61K	$356.42K	$563.40K	$495.44K	$571.83K	$507.36K	$498.44K	$2.15M	$1.22M	$1.96M	$1.89M	$-8.91M	$1.91M	$1.83M	$1.86M	$1.55M	$-8.18M	$-8.00M	$-5.97M	$-6.99M	$-5.23M
Low Forecast	$-3.56M	$-3.21M	$-2.98M	$-3.14M	$-4.17M	$-3.76M	$-3.49M	$-3.68M	$-4.67M	$-4.21M	$-3.91M	$-6.19M	$-5.44M	$-6.28M	$-5.57M	$-5.47M	$-9.49M	$-13.41M	$-21.49M	$-20.80M	$-10.36M	$-21.02M	$-20.08M	$-20.42M	$-17.06M	$-8.18M	$-8.00M	$-8.95M	$-6.99M	$-5.23M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	0.98%	0.72%	0.99%	0.85%	0.97%	1.03%	0.35%	-0.34%

Lumos Pharma's average Quarter net income forecast for Dec 20 is $-6.99M, with a range of $-6.99M to $-6.99M. LUMO's average Quarter net income forecast represents a -496.21% decrease compared to the company's last Quarter net income of $1.76M (Sep 20).

Lumos Pharma SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	1	1	1	1	4	4	11	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.89M	$4.15M	$4.36M	$4.49M	$3.92M	$3.68M	$3.62M	$4.63M	$5.16M
Avg Forecast	$73.07M	$69.48M	$66.05M	$62.80M	$59.71M	$56.77M	$53.97M	$51.32M	$48.79M	$46.39M	$44.10M	$41.93M	$6.40M	$6.40M	$6.40M	$6.40M	$227.50M	$12.91M	$11.31M	$12.80M	$74.66K	$9.62M	$15.58M	$9.49M	$4.88M	$2.84M	$789.17K	$4.58M	$1.07M	$110.91M
High Forecast	$140.47M	$133.56M	$126.98M	$120.73M	$114.78M	$109.13M	$103.76M	$98.65M	$93.79M	$89.17M	$84.78M	$80.61M	$12.30M	$12.30M	$12.30M	$12.30M	$443.46M	$24.81M	$21.73M	$24.60M	$143.52K	$9.62M	$29.95M	$18.24M	$9.38M	$2.84M	$789.17K	$5.49M	$1.07M	$110.91M
Low Forecast	$5.61M	$5.33M	$5.07M	$4.82M	$4.58M	$4.35M	$4.14M	$3.94M	$3.74M	$3.56M	$3.38M	$3.22M	$490.83K	$490.83K	$490.83K	$490.83K	$11.31M	$989.90K	$867.16K	$981.71K	$5.72K	$9.61M	$1.19M	$727.78K	$374.11K	$2.84M	$789.17K	$3.66M	$1.07M	$110.91M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.40%	0.27%	0.46%	0.92%	1.38%	4.67%	0.79%	4.34%	0.05%

Lumos Pharma's average Quarter SG&A projection for Dec 23 is $74.66K, based on 2 Wall Street analysts, with a range of $5.72K to $143.52K. The forecast indicates a -98.08% fall compared to LUMO last annual SG&A of $3.89M (Sep 23).

Lumos Pharma EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	1	1	1	1	4	4	11	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.04	$-0.00	$-0.81	$-0.92	$-0.83	$-0.93	$-0.92	$-0.29	$0.21
Avg Forecast	$-0.19	$-0.18	$-0.16	$-0.17	$-0.23	$-0.21	$-0.19	$-0.20	$-0.26	$-0.23	$-0.21	$-0.34	$-0.30	$-0.34	$-0.30	$-0.30	$-0.45	$-0.73	$-1.17	$-1.14	$-1.14	$-1.15	$-1.10	$-1.11	$-0.93	$-1.01	$-0.99	$-0.89	$-0.86	$-0.65
High Forecast	$0.04	$0.04	$0.03	$0.03	$0.05	$0.04	$0.04	$0.04	$0.05	$0.05	$0.04	$0.07	$0.06	$0.07	$0.06	$0.06	$0.26	$0.15	$0.23	$0.23	$-1.07	$0.23	$0.22	$0.22	$0.19	$-1.01	$-0.99	$-0.89	$-0.86	$-0.65
Low Forecast	$-0.43	$-0.39	$-0.36	$-0.38	$-0.50	$-0.45	$-0.42	$-0.44	$-0.56	$-0.51	$-0.47	$-0.74	$-0.65	$-0.75	$-0.67	$-0.66	$-1.14	$-1.61	$-2.58	$-2.50	$-1.24	$-2.52	$-2.41	$-2.45	$-2.05	$-1.01	$-0.99	$-0.89	$-0.86	$-0.65
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.91%	0.00%	0.73%	0.99%	0.82%	0.94%	1.03%	0.34%	-0.33%

According to 9 Wall Street analysts, Lumos Pharma's projected average Quarter EPS for Dec 20 is $-0.86, with a low estimate of $-0.86 and a high estimate of $-0.86. This represents a -510.48% decrease compared to LUMO previous annual EPS of $0.21 (Sep 20).

Lumos Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.26	$15.00	1090.48%	Buy
STTK	Shattuck Labs	$1.11	$12.00	981.08%	Hold
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
LUMO	Lumos Pharma	$4.32	$16.50	281.94%	Buy
RZLT	Rezolute	$5.01	$13.50	169.46%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
ERAS	Erasca	$2.64	$6.50	146.21%	Buy

LUMO Forecast FAQ

Is Lumos Pharma a good buy?

Yes, according to 5 Wall Street analysts, Lumos Pharma (LUMO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of LUMO's total ratings.

What is LUMO's price target?

Lumos Pharma (LUMO) average price target is $16.5 with a range of $7 to $26, implying a 281.94% from its last price of $4.32. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Lumos Pharma stock go up soon?

According to Wall Street analysts' prediction for LUMO stock, the company can go up by 281.94% (from the last price of $4.32 to the average price target of $16.5), up by 501.85% based on the highest stock price target, and up by 62.04% based on the lowest stock price target.

Can Lumos Pharma stock reach $6?

LUMO's average twelve months analyst stock price target of $16.5 supports the claim that Lumos Pharma can reach $6 in the near future.

What are Lumos Pharma's analysts' financial forecasts?

Lumos Pharma's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $5.2M (high $9.99M, low $398.73K), average EBITDA is $-5.198M (high $-399K, low $-9.993M), average net income is $-6.866M (high $1.38M, low $-15.099M), average SG&A $221.77M (high $426.32M, low $17.01M), and average EPS is $-0.825 (high $0.165, low $-1.813). LUMO's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $6.36M (high $12.23M, low $487.97K), average EBITDA is $-6.362M (high $-488K, low $-12.229M), average net income is $-5.86M (high $1.17M, low $-12.887M), average SG&A $271.41M (high $521.74M, low $20.82M), and average EPS is $-0.704 (high $0.141, low $-1.547).

Did the LUMO's actual financial results beat the analysts' financial forecasts?

Based on Lumos Pharma's last annual report (Dec 2023), the company's revenue was $2.05M, beating the average analysts forecast of $814.72K by 151.74%. Apple's EBITDA was $-36.614M, beating the average prediction of $-815K by 4394.08%. The company's net income was $-34.034M, missing the average estimation of $-37.454M by -9.13%. Apple's SG&A was $16.57M, missing the average forecast of $34.76M by -52.33%. Lastly, the company's EPS was $-0.0042, missing the average prediction of $-4.498 by -99.91%. In terms of the last quarterly report (Sep 2023), Lumos Pharma's revenue was $7K, missing the average analysts' forecast of $225.4K by -96.89%. The company's EBITDA was $-8.932M, beating the average prediction of $-225K by 3862.73%. Lumos Pharma's net income was $-8.3M, missing the average estimation of $-9.56M by -13.18%. The company's SG&A was $3.89M, missing the average forecast of $9.62M by -59.52%. Lastly, the company's EPS was $-1.04, missing the average prediction of $-1.148 by -9.41%